MedPacto Completes First Patient Enrollment in Phase 2 Osteosarcoma Trial for Vactosertib

MedPacto, an innovative new drug developer, announced on September 23 that it has successfully completed the first patient enrollment in a Phase 2 clinical trial for its immuno-oncology candidate, Vactosertib, targeting osteosarcoma.

MedPacto is currently conducting clinical trials in both Korea and the United States, targeting adult and adolescent patients with osteosarcoma.

With the start of the Phase 2 trial for adults, the company expanded the number of domestic clinical sites from the previous three-National Cancer Center, Korea Cancer Center Hospital, and Seoul National University Bundang Hospital-to a total of six, adding Seoul National University Hospital, Asan Medical Center, and Samsung Medical Center. MedPacto plans to accelerate patient recruitment as a result.

Prior to entering Phase 2, MedPacto confirmed better-than-expected therapeutic responses in Phase 1. In patients with relapsed or refractory osteosarcoma, Vactosertib monotherapy achieved a partial response (PR) rate of over 35%.

Building on these results, MedPacto will present follow-up data from the Phase 1 osteosarcoma study of Vactosertib at the Society for Immunotherapy of Cancer (SITC) in Maryland, USA, and at Bio Europe in Vienna, Austria, both taking place in November.

A MedPacto representative stated, "With very positive clinical results, we are receiving significant interest and expectations from major hospitals in Korea and medical professionals in the United States. If we secure meaningful interim data in Phase 2, full-scale licensing negotiations are expected to begin."

Vactosertib has been designated as an orphan drug in both the United States and Europe, and has also received Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA). MedPacto is also in discussions with the FDA for Breakthrough Therapy designation for Vactosertib.

This content was produced with the assistance of AI translation services.